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No data are present in the literature regarding chemokine (CXC motif) ligand (CXCL)9 and CXCLll
circulating levels in cryoglobulinemia associated with hepatitis C (MC+HCV), in presence/absence of
autoimmune thyroiditis (AT). Serum CXCL9 and CXCLll have been measured in 38 MC+HCV patients
without AT (MCo), 38 MC+HCV patients with AT (MC+AT), and in matched controls without (control
1) or with thyroiditis (control 2). Serum CXCL9 and CXCLll were significantly higher: in control
2 than control 1 (p<O.05); in MCo than control 1 and control 2 (p<O.OOI, for both); in MC+AT than
control 1 and control 2 (p<O.OOOI, for both), and than MCo (p=O.OI, for both). Our study demonstrates
markedly high serum levels of CXCL9 and CXCLll in patients with MC+HCV compared to healthy
controls; in MC+HCV patients increased CXCL9 and CXCLlllevels were significantly associated with
the presence of AT. Moreover, a strong relation between circulating CXCL9 and CXCLll in MC+HCV
has been shown.
Monokine induced by interferon (IFN)-y, also
known as chemokine (CXC motif) ligand (CXCL)9,
IFN-inducible T cell a chemoattractant (CXCLlI),
and IFN-y-induced protein IO/CXCLlO, are
members of a CXC chemokine subfamily that acts
via the CXC chemokine receptor 3 (1,2), expressed
on activated T-helper (Th)l. CXCL9, CXCLlO and
CXCLll are "IFN-y inducible chemokines", and
they recruit activated Thl lymphocytes to sites of
inflammation.
Recent evidence has shown that CXC
u-chemokine CXCL I0 plays an important role in
the active phases of mixed cryoglobulinemia (Me).
In fact, circulating CXCLl 0 is high in particular in
cryoglobulinemic patients with active vasculitis,
suggesting a prevalence of the Thl immune response
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in this phase (3, 4).
Furthermore, it has been shown CXCLl° is
higher in MC with autoimmune thyroiditis (AT),
with respect to those without (5,6), accordingly with
other studies in patients with autoimmune disorders
without HCV infection (7, 8).
No study has evaluated CXCLlI, together
with CXCL9, circulating levels in patients with
cryoglobulinemia associated with hepatitis C
(MC+HCV), with or without AT. Furthermore, a few
studies evaluated CXCL9 and CXCL II in thyroid
autoimmunity. In fact, it has been recently shown
that CXCL9 and CXCL II circulating levels are
higher in patients with AT (9), and that the secretion
of CXCL9 and CXCL II in primary cultures of
human thyrocytes can be stimulated by IFN-y and
tumor necrosis factor-a (10, 11). These data suggest
that CXCL9 and CXCL 11 chemokines are involved
in the Th I immune response that is pathogenetically
associated with the initial phase of AT.
The aim of the present study therefore was to
measure serum CXCL9 and CXCLlI levels in
patients with MC+HCV, with or without AT, and to
relate the findings to the clinical phenotype.
MATERIALS AND METHODS
Patients with MC+HCV
Thirty-eight MC+HCY patients without autoimmune
thyroiditis (MCo), and 38 patients with MC+HCY and
autoimmune thyroiditis (MC+AT), consecutively referred
to the Rheumatology Unit ofthe University ofModena and
Reggio Emilia were recruited into the study (enrolment
start date, January 1995). The diagnosis ofMC was based
on the presence of serum mixed (IgG-lgM) cryoglobulins
and the classical clinical triad - purpura, weakness,
arthralgias - and on the exclusion of other well-known
systemic disorders, such as immuno-rheumatic, neoplastic,
and infectious diseases (12, 13). HCY infection was
systematically evaluated in all patients, and HCY negative
were excluded. Only patients with MC+HCY, without
liver cirrhosis (by histology, laboratory evidence of liver
failure and/or ultrasound-proven portal hypertension)
(14) and without hepatocellular carcinoma, in whom a
thyroid screening [history, physical examination, thyroid-





) , anti-thyroglobulin (AbTg) and anti-
thyroid peroxidase (AbTPO) antibodies measurements
and ultrasonography] excluded (MCo), or revealed
(MC+AT) the presence of associated thyroid autoimmune
disorders, were included in these groups.
Fifty-one out of 76 (67%) MC+HCY patients
underwent liver biopsy for diagnostic purposes; the mean
activity index (grade) was 5.3±1.1, and the stage was
2.2±0.6; mean alanine aminotransferase (ALT) serum
levels were 53±44 (reference values, 5-36 lUlL); high
levels of Rheumatoid Factor were present in 98% of
MC+HCY patients.
The main demographic and clinico-serological
features of MCo patients are reported in Table 1. Among
them, 20 had been previously treated with IFN-a for an
average of7.2 months (range 1-14), at a mean dosage of
9 MU/week (range 3-9); the time elapsed from the last
course of IFN-a treatment ranged from 5 to 92 months
(mean 44). No statistically significant difference was
observed in the main demographic and clinico-serological
features of MC patients treated (MC/IFN+) or untreated
(MC/IFN-) with IFN-a.
At the time of the study, 21 MCo patients were taking
low doses of corticosteroids, 8 had previously been
on corticosteroids and 9 had never been treated with
corticosteroids. No MC patient had had plasma exchange
treatment in the last year before the study. The presence of
Raynaud's phenomenon, Sjogren's syndrome, skin ulcers,
peripheral neuropathy, and renal and liver involvement
in MCo patients was evaluated as previously described
(12). Routine blood chemistry was carried out by standard
methods.
The main demographic and clinico-serological features
of MC+AT patients are reported in Table 1. Among them,
20 had been previously treated with IFN-a for an average
of 5.9 months (range 1-12), at a mean dosage of 12 MUI
week (range 3-10); the time elapsed from the last course
of IFN-a treatment ranged from 3 to 65 months (mean
37). No statistically significant difference was observed in
the main demographic and clinico-serological features of
MC patients treated (MC/IFN+) or untreated (MC/IFN-)
with IFN-a.
At the time of the study, 21 MC+AT patients were
taking low doses ofcorticosteroids, 6 had previously been
on corticosteroids and II had never been treated with
corticosteroids. No MC patient had had plasma exchange
treatment in the last year before the study. The presence of
Raynaud's phenomenon, Sjogren's syndrome, skin ulcers,
peripheral neuropathy, and renal and liver involvement in
MC+AT patients was evaluated as previously described
(12). Routine blood chemistry was carried out by standard
methods.
Controls
Two control groups were included, extracted from a
random sample of the general population from the same
geographic area (15).
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The first control group (control 1) consisted of 38
subjects, matched by gender and age [that is a well known
confounding factor (16)] with MCo patients, without HCY
infection or other liver disorders, in whom a complete





, AbTg, AbTPO, and ultrasonography) was available,
and excluded the presence of thyroid or autoimmune
disorders, or any kind of immunomodulant therapy.
The second control group (control 2) consisted of
38 subjects, matched by gender and age [that is a well
known confounding factor (16)] with MC+AT patients,
without HCY infection or other liver disorders, in whom a





, AbTg, AbTPO, and ultrasonography)
was available, and demonstrated the presence of thyroid
autoimmune disorders, but excluded the presence ofother
autoimmune disorders and any kind of immunomodulant
therapy.
In all patients and controls, a blood sample was
collected in the morning, after overnight fasting, and serum
was kept frozen until CXCL9 and CXCL 11 measurement.
All study subjects gave their informed consent to the
study, which was approved by the local Ethics Committee.
Immunological studies
Cryocrit was measured as the percentage of packed
cryoglobulins after cold centrifugation of the serum;
cryoglobulin composition was determined by including
the presence in cryoprecipitates of monoclonal or
polyclonal IgM-rheumatoid factor, (i.e. MC type II or MC
type III); haemolytic complement activity (CH50) and
C3-C4 fractions were measured as previously described
(12); anti-nuclear (ANA), anti-smooth muscle (ASMA),
and anti-mitochondrial (AMA) autoantibodies were
detected by current techniques (12). Sera with a titre>
1:40 were considered positive. Anti-extractable nuclear
antigen (ENA) antibodies, including anti-Scl70, anti-Sm,
-RNP, -SSAISSB, -PCNA, -SL and -101 specificities, were
detected by counter-immunoelectrophoresis as previously
reported (14).
Virological studies
Anti-HCY antibodies and HCY RNA were determined
on serum clotted and centrifuged at 37°C and stored
at -70°C. Antibodies against HCY (anti-HCY) were
detected by an enzyme-linked immunoassay (Chiron
ELISA HCY, Second Generation; Emeryville CA, USA).
A recombinant-based immunoblot assay (Chiron RIBA
HCV, Second Generation Assay; Emeryville CA, USA)
was used to investigate the specificity of anti-HCY
seropositivity. The presence of HCY RNA in the serum
was investigated by a polymerase chain reaction (PCR)
technique as previously described (17). Amplification of
HCY cDNA was performed using a 'nested' PCR, with
primers located in the 5' non-coding region (17). The
analysis of amplification products was performed by
both ethidium bromide staining and hybridisation with
a radiolabelled oligonucleotide probe internal to the
amplified sequence.
Ultrasonography of the neck and fine-needle aspiration
(FNA)
Neck ultrasonography was performed by the same
operator, who was unaware of the results of thyroid
hormones, autoantibodies and CXCLl 0 measurements,
using a probe (Esaote, Florence, Italy; AU5 with a sectorial
7.5 MHz transducer). Thyroid volume was calculated
using the ellipsoid formula, as described (7). The presence
of hypoechoic and dyshomogeneous echogenicity was
arbitrarily rated at three levels (O=normal echogenicity;
1=slight hypoechoic and dyshomogeneous; 2=severely
hypoechoic and dyshomogeneous) in order to evaluate
structural abnormalities of thyroid tissue associated
with thyroid autoimmunity (7). The presence of thyroid
nodules was recorded, and nodules with a diameter>10
mm were submitted to ultrasonography-guided FNA,
which was performed by the same operator, using a free-
hand method as already described (7).
Thyroid bloodjiow (TBF)
TBF by color-flow doppler (CFD) was studied in all
patients (7). The CFD pattern was defined as: normal (or
type 0), TBF limited to peripheral thyroid arteries; type I,
TBF mildly increased; type II, TBF clearly increased; or
type III, TBF markedly increased (7). In AT patients TBF
bore no relation to the thyroid status, and was type 0 in
58%, type I in 34%, type II in 8% of patients, while none
had type III CFD pattern.
Laboratory evaluation
Thyroid function and thyroid autoantibodies were
measured as previously described (7). Circulating FT and
FT were measured by commercial radioimmunoassay kits
(AMERLEX-MAB FT 1FT Kit; Amersham Biosciences,
Little Chalfont, UK). Seruk TSH (DiaSorin, Saluggia,
Italy), AbTPO and AbTg (lCN Pharmaceuticals, Costa
Mesa, CA, USA) were evaluated by immunoradiometric
assay methods. For AbTg, AbTPO, positivity was set at
>50, and> 10 IU/mL, respectively.
Serum CXCL9 andCXCLI1enzyme-linkedimmunosorbent
assay
Serum CXCL9 and CXCLll levels were assayed by
a quantitative sandwich immunoassay (R&D Systems,
Minneapolis, MN, USA). Sensitivity ranged from 1.3-
12.7 pg/mL with a mean minimum detectable dose of 3.4
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pg/mL for CXCL9; the intra- and inter-assay coefficients
of variation were 4.1% and 6.4%. The CXCL II sensitivity
ranged from 0.4-3.7 pg/mL with a mean minimum
detectable dose of 11.8 pg/mL; the intra- and inter-assay
coefficients of variation were 4.2% and 6.7%.
Data analysis
Values are given as mean±standard deviation (SD) for
normally distributed variables, otherwise as median and
[interquartile range]. Mean group values were compared
by using one-way analysis of variance (ANOVA) for
normally distributed variables (age and body mass index),
otherwise by the Mann-Whitney U or Kruskal-Wallis
test. Proportions were compared by the X2 test. Post-
hoc comparisons on normally distributed variables were
carried out using the Bonferroni-Dunn test. Univariate
and multivariate analysis were performed by simple or
multiple linear regression analysis. Statistical power (ex
post analysis) (stat-power) was calculated.
RESULTS
MCo and MC+AT patients were not significantly
different in relation to the clinical phenotype of
cryoglobulinemia (Table I). The demographic and
clinical thyroid features of patients and controls
are reported in Table II. As expected, MC+AT
patients, and controls with AT (control 2) showed
significantly higher thyroid autoantibodies levels,
as well as hypoechogenicity and hypervascularity of
the thyroid gland, and subclinical hypothyroidism in
comparison to control 1 and MCo.
Serum CXCL9 levels were significantly (Table
II) higher in control 2 thyroiditis, than in control
I (p<0.01). MCo have serum CXCL9 levels
significantly (p<0.000 1) (stat-power= 1) higher
than control 1 without thyroiditis (Fig. 1) and
controls 2 with thyroiditis. MC+AT have serum
CXCL9 levels significantly higher (p<0.000 1) (stat-
power=l) than control 1 and 2 (Fig. 1), or MCo
(p=0.01) (stat-power=0.8). Serum CXCL9 levels
were not associated with any of the clinical features
of cryoglobulinemia in patients MCo and MC+AT
(data not shown).
Serum CXCLll levels were significantly (Table
II) higher in control 2 thyroiditis, than in control
1 (p=0.02). MCo have serum CXCLll levels
significantly higher than control 1 and control 2
(p<0.001, for both) (stat-power=l) (Fig. 2). MC+AT
have serum CXCL 11 levels significantly higher than
control 1 and 2 (p<0.0001, for both) (stat-power=l)
(Fig. 2), and than MCo (p=0.01) (stat-power=0.8).
Serum CXCLII levels were not associated with
any of the clinical fetaures of cryoglobulinemia in
patients MCo and MC+AT (data not shown).
In order to better define the role of increased
serum chemokines in AT, CXCL9 and CXCLll were
studied in relation to clinical features of AT (age;
gender; thyroid volume <6 mL; thyroid hypoechoic
pattern, or hypervascularity; AbTg or AbTPO
positivity; subclinical hypothyroidism) in MC+AT
patients and control 2, without any significant result.
By defining a high CXCL9 level as a value of at
least 2 SD above the mean value of the control group
(>125 pg/mL), 4% of control 1,29% of control 2,
87% ofMCo and 98% ofMC+AT, had high CXCL9
(p<0.0001; x2test).
By defining a high CXCL 11 level as a value of at
least 2 SD above the mean value of the control group
(>110 pg/mL), 4% of control 1, 28% of control 2,
88% ofMCo and 98% ofMC+AT, had high CXCLll
(p<0.000 1; X2test).
No significant association was observed in
relation to the presence or absence of active or
previous treatments, or in relation to the duration of
MC, and CXCL9 or CXCLll circulating levels.
In a simple regression analysis CXCL9 and
CXCL 11 serum levels were significantly related
to each other (r=0.547, p<O.OOOl) in MC+HCY
patients.
DISCUSSION
Our study first demonstrates high serum levels
of CXCL9 and CXCL 11 chemokine in patients with
MC, in particular in the presence of AT. Moreover,
to the best of our knowledge, we have first shown
strong association between CXCL9 and CXCLll
circulating levels in these patients, strongly
supporting the role ofa Thl immune response in the
pathogenesis ofMC+HCV.
Our results agree with those of other
studies in patients with HCY infection without
cryoglobulinemia.
Increased circulating levels of CXCL9 (18-22)
and CXCLll (18, 20, 23), were observed in some
studies, while other studies were no able to show any
significant difference with controls (24). Bieche et
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Age (years) 61±13 64±11
Men/Women 9/29 7/31





Raynaud's phenomenon 46% 49%
Sjogren's syndrome 43% 44%
Peripheral neuropathy 62% 55%
Renal invo1vement* 15% 12%
Cryocrit (%) 4.1±1O.3 4.7±9.1
CH50 (normal: 160-220 units) 116±38 113±37
C3 (normal: 60-130 mg/dL) 86±38 81±36
C4 (norma1:20-55 mg/dL) 15±16 13±15
Autoantibodies t 25% 33%
* Serum creatinine> 1.5 mg/dL and/or proteinuria >0.5 gr/24h. t Presence ofANA and/or AMA and lor ASMA and/or
anti-ENA No significant difference was observed regarding the the above-mentioned characteristics in the 2 groups.
al. studied the expression of 240 genes in patients
with HCY chronic infection (25). They showed
mRNA level up-regulation of IFN-y-inducible genes
(CXCL9, CXCLlO, CXCLlI). These results suggest
that CXCL9 and CXCLlI, potent chemo attractants
for activated T cells, are produced by hepatocytes in
the HCY-infected liver and play an important role in
the pathogenesis ofMC.
In our MC+HCY patients CXCL9 and CXCLll
serum levels were significantly higher than in
controls. The possible contribution of chronic
hepatitis C to high CXCL9 and CXCLlI serum
levels in MC+HCY patients cannot be excluded.
Furthermore, the increase of CXCL9 and CXCL II
is in agreement with recent evidences, that have
shown that CXCLl°plays an important role in
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Table II. Thyroid status and circulating levels ofCXCL9 and CXCLl}, in control subjects (control L), control with au-
toimmune thyroiditis (control 2), patients with HCV-related MC without (MCo) or with autoimmune thyroiditis (MC+AT).
controls 1 controls 2 MCo MC+AT p
thyroiditis
n 38 38 38 38
Age (years) 63±1 I 62±13 61±I3 64±11 ns
Gender (M/F) 8/30 7/3 I 9/29 7/3 I ns
Thyroid volume (mL) 9±10 13±12 IO±II 11±14 ns
Hypoechoic (%) 0 71° 0 83° 0.0001
Hypervascular (%) 0 43° 0 48° 0.0001
Serum TSH (ul.I/ml.) 1.2±0.8 I. 6±1.7 1.I±1.I 2.8±3.4* 0.001
AbTPO (IU1mL) IO±IO 267±361° 11±9 348±325° 0.0001
AbTg (IU/mL) I l± 12 326±224° 9±11 252±273° 0.0007
Anti-thyrotropin-receptor
0 0 0 0 ns
antibody (TRAb) (IUlmL)
AbTPO positivity (%) 0 81 0 88 0.0001
AbTg positivity (%) 0 78 0 81 0.0001
Subclinical hypothyroidim
0 5° 0 39° 0.002
(%)
CXCL9 (pg/mL) 69±28 151±91§ 403±149" 507±232* <0.0001
CXCLII (pg/mL) 60±25 139±84§ 256±197" 348±279* <0.0001
Anti-thyroperoxidase antibody: AbTPO; Anti-thyroglobulin antibody: AbTg; Thyroid-stimulating hormone: TSH; Anti-
thyrotropin-receptor antibody:TRAb *p <0.05 or less vs controls} or vs autoimmune thyroiditis control 2, or vs MCo °
p<0.05 or less vs controls} and vs MCo § p<O. 05 or less vs controls} /\p <0.05 or less vs controls} or vs autoimmune
thyroiditis control 2
cryoglobulinemia. In fact, circulating CXCLl 0 is
high in particular in cryoglobulinaemic patients with
active vasculitis, suggesting a prevalence of the Thl
immune response in this phase (3, 4).
In our study we did not find any relation among
serum CXCL9 or CXCLlI levels and the duration
of MC+HCV, probably because the disease is
characterized by a relapsing clinical course whose
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most common expression are vasculitic symptoms
(26). Clinico-pathological alterations of MC+HCY
may recognize at least two synergical pathogenetic
mechanisms triggered by HCY. Firstly, B-cell
proliferation leads to immune-complexes production
(cryoglobulins) (26), that are responsible for
immune-complex-mediated vasculitis (13, 26), while
high serum CXCL9 and CXCLlI levels secondary
to both HCY-related vascular and hepatic cell injury
may amplify the inflammatory process through Thl-
mediated immune response.
Change of serum chemokine levels in the
course of other autoimmune disorders has been
demonstrated. Recent experimental evidence has
demonstrated that CXC chemokines and particularly
CXCLl 0 play an important physiopathological role
in the initial phases ofautoimmune thyroid disorders
(7, 27). Furthermore, we have recently shown that
increased serum CXCLl 0 levels in patients with
Graves' disease (GD) are associated mainly with the
active phase of GD, not related to hyperthyroidism
itself, but mainly to autoimmune response (8).
Interestingly, this study first shows serum CXCL9
and CXCLlI were higher in MC+AT patients with
respect to MCo, such as in AT patients with respect
to controls without AT, in agreement with the above-
mentioned studies. Furthermore, it has been recently
shown that CXCL9 and CXCL 11 circulating levels
in AT patients were associated with high serum TSH
concentrations, suggesting that raised CXCL9 and
CXCLlI chemokines are not only associated with
the autoimmune process itself, but may be a marker
of a thyroiditic process eventually leading to the
destruction of thyroid follicular cells (9, 28).
We were not able to find any relationship among
CXCL9 or CXCLlllevels and hypothyroidism in the
present study,probably because ofthe limited number
of patients studied. Longitudinal studies evaluating
serum CXCL9 and CXCLlllevels in large MC+HCY
patient series will be necessary to evaluate whether
serum CXCL9 or CXCL11 measurement could
represent an easily detectable prognostic marker for
clinical management of MC+HCY patients, with or
without thyroiditis.
Recently, it was shown that a low baseline
CXCL10 level was significantly associated with low
baseline viral load, rapid viral response, and sustained






















Ctrl Ctrl +TA MC MC+TA
Fig. 1. Serum CXCL9 levels in patients with MC+HCV
with or without AT and controls. Serum CXCL9 levels
were significantly (*) higher in control 2 with thyroiditis
(Ctrl+AT), than in control 1 (Ctr/) (p<O.Ol). MC+HCV
patients (MC) have serum CXCL9leveis significantly (**)
(p<O.OOOl) (stat-power=l) higher than control I without
thyroiditis (Ctr/) and controls 2 with thyroiditis (Ctrl+TA).
MC+HCVpatients with AT (MC+TA) have serum CXCL9
levels significantly (***) higher (p<O.OOOl) (stat-
power=l) than control 1 (Ctrl) and 2 (Ctrl+TA), or MC
(p=O.Ol) (ANOVA) (stat-power=O.8). The box indicates
the lower and upper quartiles and the central line is the
median value; the horizontal lines at the end ofthe vertical
lines are the 2.5% and 97.5% values.
Ctri Ctri+TA MC MC+TA
Fig.2. Serum CXCLll levels in patients with MC+HCV
with or without AT and controls. Serum CXCLll levels
were significantly (*) higher in control 2 with thyroiditis
(Ctrl+TA), than in control 1 (Ctrl) (p=O.02). MC+HCV
patients (MC) have serum CXCLll levels significantly
(**) higher than controll (Ctr/) and control 2 (Ctrl+TA)
(p<O.OOl, for both) (stat-power=l). MC+HCV patients
with AT (MC+TA) have serum CXCLlllevels significantly
(***) higher than control 1 (Ctr/) and 2 (Ctrl+TA)
(p<O.OOOl, for both) (stat-power=l), and than MC
(p=O.Ol) (ANOVA) (stat-power=O.8). The box indicates
the lower and upper quartiles and the central line is the
median value; the horizontal lines at the end ofthe vertical
lines are the 2.5% and 97.5% values.
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(29-31 ).
In another study, levels of CXCLl 0 and CXCL9
decreased following successful antiviral therapy in
HCY+ patients, while CXCLll did not decline (18).
Since IFN-a is a well known effective therapy
for MC+HCY (26), pretreatment evaluation of
serum of CXCL9 or CXCLlI levels might suggest
the virological response to IFN also in MC+HCY
patients.
Interestingly, to the best of our knowledge, this is
the first demonstration of a strong relation between
circulating CXCL9 and CXCL 11, in a human
pathology, such as MC+HCY in presence or absence
ofAT. This finding strongly supports the role ofa Th1
immune response in the pathogenesis of MC+HCV.
In conclusion, our study demonstrates markedly
high serum levels ofCXCL9 and CXCLll in patients
with MC+HCY compared to healthy controls; in
MC+HCY patients increased CXCL9 and CXCLll
levels were significantly associated with the presence
ofAT. Moreover, a strong relation between circulating
CXCL9 and CXCL 11, in MC+HCY has been shown.
Future studies in larger cohort of patient will be
needed to evaluate the relevance ofserum CXCL9 and
CXCLll in the therapeutic approach to these patients.
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